FDA Clears ArkBio to Begin Phase II Clinical Trial for Novel Influenza Prevention Drug AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406. This clearance allows ArkBio to initiate a Phase II clinical trial in the United States for AK0406, a long-acting antiviral drug-Fc conjugate (AFC) designed for influenza prevention in the general population.